Literature DB >> 20004701

Melatonin is released in the third ventricle in humans. A study in movement disorders.

José Leston1, Catherine Harthé, Jocelyne Brun, Carmine Mottolese, Patrick Mertens, Marc Sindou, Bruno Claustrat.   

Abstract

In order to determine sources and metabolism of melatonin in human cerebrospinal fluid (CSF), melatonin and 6-sulfatoxymelatonin (aMT6S) concentrations were measured in CSF sampled during neurosurgery in both lateral and third ventricles in patients displaying movement disorder (Parkinson's disease, essential tremor, dystonia or dyskinesia) and compared with their plasma levels. Previous determinations in nocturnal urine had showed that the patients displayed melatonin excretion in the normal range, compared with healthy controls matched according to age. A significant difference in melatonin concentration was observed between lateral and third ventricles, with the highest levels in the third ventricle (8.75+/-2.75 pg/ml vs. 3.20+/-0.33 pg/ml, p=0.01). CSF aMT6s levels were similar in both ventricles and of low magnitude, less than 5 pg/ml. They were not correlated with melatonin levels or influenced by the area of sampling. Melatonin levels were significantly higher in third ventricle than in the plasma, whereas there was no difference between plasma and lateral ventricle levels. These findings show that melatonin may enter directly the CSF through the pineal recess in humans. The physiological meaning of these data remains to be elucidated. (c) 2009. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004701     DOI: 10.1016/j.neulet.2009.12.008

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

1.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

2.  Melatonin Attenuates Manganese and Lipopolysaccharide-Induced Inflammatory Activation of BV2 Microglia.

Authors:  Euteum Park; Hong Sung Chun
Journal:  Neurochem Res       Date:  2016-11-30       Impact factor: 3.996

Review 3.  Extrapineal melatonin: sources, regulation, and potential functions.

Authors:  Darío Acuña-Castroviejo; Germaine Escames; Carmen Venegas; María E Díaz-Casado; Elena Lima-Cabello; Luis C López; Sergio Rosales-Corral; Dun-Xian Tan; Russel J Reiter
Journal:  Cell Mol Life Sci       Date:  2014-02-20       Impact factor: 9.261

4.  Neurotoxins: free radical mechanisms and melatonin protection.

Authors:  Russel J Reiter; Lucien C Manchester; Dun-Xian Tan
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

5.  Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Authors:  Venkatramanujam Srinivasan; Charanjit Kaur; Seithikurippu Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2010-12-08

6.  Significance of high levels of endogenous melatonin in Mammalian cerebrospinal fluid and in the central nervous system.

Authors:  Dun-Xian Tan; Lucien C Manchester; Emilio Sanchez-Barcelo; Maria D Mediavilla; Russel J Reiter
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

7.  Melatonin metabolism in the central nervous system.

Authors:  Rüdiger Hardeland
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

8.  Clinical aspects of melatonin intervention in Alzheimer's disease progression.

Authors:  Daniel P Cardinali; Analía M Furio; Luis I Brusco
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

9.  Melatonin in mitochondrial dysfunction and related disorders.

Authors:  Venkatramanujam Srinivasan; D Warren Spence; Seithikurippu R Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2011-05-04

Review 10.  Can melatonin help us in radiation oncology treatments?

Authors:  Ehsan Mihandoost; Alireza Shirazi; Seied Rabie Mahdavi; Akbar Aliasgharzadeh
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.